With the exception of the oxidation of G6P (glucose 6-phosphate) by H6PDH (hexose-6-phosphate dehydrogenase), scant information is available about other endogenous substrates affecting the redox state or the regulation of key enzymes which govern the ratio of the pyridine nucleotide NADPH/NADP. In isolated rat liver microsomes, NADPH production was increased, as anticipated, by G6P; however, this was strikingly amplified by palmitoylcarnitine. Subsequent experiments revealed that the latter compound, well within its physiological concentration range, inhibited 11β-HSD1 (11β-hydroxysteroid dehydrogenase 1), the bidirectional enzyme which interconnects inactive 11-oxo steroids and their active 11-hydroxy derivatives. Notably, palmitoylcarnitine also stimulated the antithetical direction of 11β-HSD1 reductase, namely dehydrogenase. This stimulation of H6PDH may have likewise contributed to the NADPH accretion. All told, the result of these enzyme modifications is, in a conjoint fashion, a sharp amplification of microsomal NADPH production. Neither the purified 11β-HSD1 nor that obtained following microsomal sonification were sensitive to palmitoylcarnitine inhibition. This suggests that the long-chain amphipathic acylcarnitines, given their favourable partitioning into the membrane lipid bilayer, disrupt the proficient kinetic and physical interplay between 11β-HSD1 and H6PDH. Finally, although IDH (isocitrate dehydrogenase) and malic enzyme are present in microsomes and increase NADPH concentration akin to that of G6P, neither had an effect on 11β-HSD1 reductase, evidence that the NADPH pool in the endoplasmic reticulum shared by the H6PDH/11β-HSD1 alliance is uncoupled from that governed by IDH and malic enzyme.
INTRODUCTION
The enzymes of the ER (endoplasmic reticulum) carry out many biochemical reactions not found in mitochondria or peroxisomes. This exclusivity is enabled, in part, by their intracellular segregation owing to a relatively impermeable and stable phospholipid bilayer membrane (for reviews, see [1] [2] [3] ). One such reaction includes the structural folding of proteins by oxidoreductases which facilitate disulfide formation and exploit O 2 as the eventual electron acceptor. This chemical process is promoted by a favourable oxidized thio/disulfide redox milieu, wherein, as in other organelles, the most abundant thiol buffer is glutathione [4, 5] . Not unforeseen then, upon consideration of this oxidative structural folding process, the documented GSH/GSSG ratio in the ER is anywhere from 1-3 % of that in the cytosol, i.e. a highly oxidative setting favouring the transfer of electrons to O 2 [6] .
Functioning in this relatively oxidized setting is the bidirectional enzyme 11β-HSD1 (11β-hydroxysteroid dehydrogenase 1), which facilitates the inter-conversion of inactive oxoglucocorticoids (cortisone or 11 dehydrocorticosterone) and their active 11-hydroxy derivatives (cortisol or corticosterone). Insofar as the flux balance for this reaction is governed by the pyridine cofactor redox state [3] and with the enzyme embedded within a highly oxidative setting, the paradox as to how 11β-HSD1 can act as a NADPH-dependent reductase has been unravelled. The explanation appears to be the near absence of ER glutathione reductase, thereby allowing the co-existence of distinct antithetical redox buffer ratios: an oxidative GSH/GSSH pair and reductive NADPH/NADP pyridine nucleotides [7] .
In vivo, 11β-HSD1 can be envisaged as a component of a co-ordinated tripartite system ( Figure 1 ). Besides the enzyme, which has a luminal orientation [8] , the other two components consist of facilitative G6P (glucose 6-phosphate) transport across the ER membrane in concert with an NADPH-generating enzyme, H6PDH (hexose-6-phosphate dehydrogenase) [9, 10] . In addition to G6P, other hexose 6-phosphates, such as fructose 6-phosphate, can likewise generate NADPH [11] . Thus these carbon compounds upon oxidation produce the requisite reducing equivalents for 11β-HSD1 reductase.
Yet other carbon compounds in intermediary metabolism, besides hexose phosphoesters, can transverse the ER membrane but, to date, no role in the regulation of 11β-HSD1 has been ascribed to any. For instance, both palmitoylcarnitine and carnitine can traverse using a membrane transport system seemingly disparate from the well-known facilitated carnitine/acylcarnitine exchange carrier found in mitochondria and peroxisomes [12] [13] [14] . Nonetheless, in microsomes, an outer-membrane CPT (carnitine palmityltransferase), CPT1, remains malonyl-CoAsensitive, whereas a CPT thought to exist in the lumen is not [15] . This sensitivity to malonyl-CoA infers that CPT1 serves as a prospective key checkpoint for ER acyl metabolism. The
Abbreviations used: 6PGDH, 6-phosphogluconate dehydrogenase; 11β-HSD1, 11β-hydroxysteroid dehydrogenase 1; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; CPT, carnitine palmitoyltransferase; DIDS, (4,4 -di-isothiocyanostilbene-2,2 -disulfonate; ER, endoplasmic reticulum; G6P, glucose 6-phosphate; G6PDH, G6P dehydrogenase; H6PDH, hexose-6-phosphate dehydrogenase; IDH, isocitrate dehydrogenase. 1 To whom correspondence should be addressed (email kmccormick@peds.uab.edu).
Figure 1 Regulation of the intraluminal NADPH/NADP ratio in the ER
Schematic diagram depicting the major intraluminal regulators of the NADPH/NADP ratio in the ER after G6P transport. Not shown is malic enzyme, which also generates NADPH. 6PG, 6-phosphogluconate; G6Pase, glucose-6-phosphatase; G6PT, G6P translocase; R5P, ribulose 5-phosphate.
carbon moieties within acylcarnitine may partake in protein acylation or be incorporated via diacylglycerol acyltransferase or acyl cholesterol acyltransferase into lipoproteins. Also, given their physico-chemical amphipathic properties, long-chain acylcarnitines can be embedded in phospholipid membranes, thereby modifying membrane molecular dynamics and enzymes therein. We found that long-chain acylcarnitines alter both the ER luminal enzymes 11β-HSD1 and carbon flux through H6PDH in a conjoint fashion as to cause a prodigious increase in the concentration of NADPH. 
MATERIALS AND METHODS

Materials
Preparation of rat microsomes
Microsomes were isolated from livers of rats according to the methods described by Raucy and Lasker [16] . All animal procedures were undertaken with approval and oversight of the Institutional Animal Care and Use Committee (IACUC) at the University of Alabama Birmingham. Briefly, all tissue samples were homogenized in an ice-bath with 4 vol. of 0.25 M sucrose and 50 mM Tris/HCl, pH 7.3. The homogenate was centrifuged for 10 min at 1000 g. The supernatant portion was removed and centrifuged for 20 min at 10 000 g. Thereafter, the subsequent supernatant was centrifuged for 60 min at 100 000 g. The resulting pellet was washed twice with the same buffer. The microsomes were resuspended at a protein concentration of 15-20 mg/ml (measured using the Bio-Rad protein assay). Intactness of the microsomes at the start and end of the assays, and following incubation with various concentrations of palmitoylcarnitine, was confirmed by latency of glucose dehydrogenase (>95 %) [17] .
In some experiments, to shed contaminating cytosolic enzymes such as G6PDH (G6P dehydrogenase) or other contaminants which may possibly adhere to microsomal membranes, the microsomes were washed with poly(ethylene glycol) [ [18] . In other experiments, the rat microsomes were sonicated three times for 20-25 s at 5
• C (Fisher Scientific). In order to measure 11β-HSD1 reductase in these broken microsomes, an NADPH-regenerating method was necessary, consisting of 2 mM G6P, 1 mM NADP, 3 mM MgCl 2 , and 12 units/ml G6PDH (final concentration).
Hepatic 11β-HSD1 purification
Purified human 11β-HSD1 was prepared from liver as described previously in detail [19] , and in compliance with German university and government policy and legislation. Human research was been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. Consent was obtained from the local Ethics Committee to purify and work with 11β-HSD1 from human tissue. Enzyme purification involved, in brief, gentle solubilization with the non-ionic detergent Emulgen 913 and addition of sodium cholate, followed by a variety of chromatographic procedures (octyl-Sepharose CL, Mono QSepharose and red Sepharose A). Prior to experiments, detergent residue was removed using Extract-Gel D (Pierce, Thermo Fisher Scientific).
Measurement of NADPH
Rat liver microsomes (1 mg/ml) were pre-incubated with modifiers in Mops/KCl buffer at 37
• C for 15 min. The reaction was initiated by adding 1 mM G6P and 1 mM NADP (final concentrations), incubated for 30 min, and terminated by freezing on solid CO 2 . For NADPH measurements, we adopted a sensitive radioisotopic method based on the conversion of 1-[
14 C]α-oxoglutarate into 14 C-labelled glutamate in the reaction catalysed by excess glutamate dehydrogenase as described previously [20] . Briefly, the reaction buffer (50 mM Hepes NaOH) contained 0.8 μM α-oxoglutarate, 0.5 μCi/ml 1-[
14 C]α-oxoglutarate, 12 units/ml glutamate dehydrogenase, 1 mM ADP and 50 mM ammonium acetate, pH 7.4. The reaction was started by adding 10 μl of sample to 90 μl of buffer mixture at 25
• C for 30 min, then stopped by adding 900 μl of ice-cold water and 9 μl of 2 M HCl. To separate [
14 C]glutamate from [ 14 C]α-oxoglutarate, samples were placed on anion-exchange Dowex-50 columns pretreated with 2 M HCl. The product of the reaction was eluted with 2 M NH 4 OH, and thereafter quantified by scintillation counter. The results were derived from a standard curve as pmol/sample (see insert in Figure 2 ).
11β-HSD1 reductase and dehydrogenase
The reductase direction of 11β-HSD1 activity (11β-dehydrocorticosterone→corticosterone) was measured in liver microsomes as described previously [21] . Microsomes (0.25 ml of a 50 μg/ml suspension) were pre-incubated with or without modifiers in Krebs buffer [10 mM Hepes, 130 mM NaCl, 4.7 mM KCl, 2 mM CaCl 2 , 1.25 mM MgSO 4 and 10 mM NaH 2 PO 4 , pH 7.4; BSA (2 %, v/v) and NaHCO 4 (10 mM) were added before use] for 10 min at 37
• C. Then G6P (5 μM) was added, and the reaction was initiated with 0.15 ml of 11-dehydrocorticosterone (final concentration 1 μM), incubated for 20 min and terminated by freezing on solid CO 2 . In some experiments, the concentration of the substrate 11-dehydrocorticosterone was varied. The corticosterone in the assay medium was determined by 3 H RIA (MP Biomedicals). In the corticosterone assay, the specific
Figure 2 Effect of palmitoylcarnitine on liver microsomal NADPH production
Isolated rat microsomes were incubated with the indicated concentrations of palmitoylcarnitine as described in the Materials and methods section, and NADPH accumulation was then determined using a coupled radiometric assay. Note that the assay contained 1 mM G6P. Results are expressed relative to control (no added palmitoylcarnitine) as means + − S.D., n = 5-6. Statistical analysis was by an unpaired t test; P values are shown. The insert shows the standard curve for the radiometric NADPH assay which detects picomolar amounts.
cross-reactivity with 11-dehydrocorticosterone (the substrate) was 5.9-6.4 %.
Dehydrogenase activity was determined by TLC as described previously [22] . Microsomes (1.0 mg/ml) were incubated with or without palmitoylcarnitine for 10 min at 37
• C, 1 mM NADP, 1 μM cortisol and [
3 H]cortisol, and incubated at 37
• C for 45-60 min. To terminate the reaction, the tubes were transferred to ice, and 3 vol. of ice-cold ethyl acetate was added to extract the steroids. The radiolabelled cortisol and cortisone were separated on silicone-coated TLC plates (Whatman). Radioactivity was counted by scintillation counter, and results are expressed as nmol/mg of protein per min.
Flux through H6PDH
The assay for carbon flux through H6PDH and 6PGDH (6-phosphogluconate dehydrogenase) in microsomes is based on the measurement of released 14 CO 2 , produced by the metabolism of radiolabelled 1-[
14 C]G6P into D-ribulose 5-phosphate [23, 24] . This in situ assay method represents flux through the first two enzymes of the pentose pathway and was chosen to preserve membrane intactness. Per mol of CO 2 released, 2 mol of NADPH are produced. The reaction mixture consisted of 0.2 mM glucose, 0.2 μCi/ml 1-[
14 C]-glucose, 1 mM ATP, 10 units hexokinase, 1 mM NADP, 1 mM MgCl 2 and 1 mg/ml of microsomes in a final volume of 100 μl. After incubating at 37
• C for 45-60 min, 60 % perchloric acid was added to terminate the reaction. The released 14 CO 2 was sequestered in suspended centre vials containing hyamine. The results are reported as nmol/mg of protein per min.
RESULTS
Effect of palmitoylcarnitine and other compounds on liver microsomal NADPH production
Rat liver microsomes were pre-incubated with increasing concentrations of palmitoylcarnitine, and NADPH production was Rat liver microsomes were incubated with 1-100 μM palmitoylcarnitine or related compounds (100 μM) for 10 min and then 11β-HSD1 reductase activity was measured as described in the Materials and methods section (note: the assay contained 5 μM G6P and the baseline enzyme rate was 0.65 + − 0.14 nmol/mg of protein per min). , Palmitoylcarnitine; ᭡, acetylcarnitine; ᭢, carnitine; ᭜, palmitate; ᭹, DIDS; ᮀ, myristolycarnitine. Results are expressed relative to control (no modifier) as means + − S.D., n = 4-5. Significant statistical comparisons by an unpaired t test are shown. measured using a coupled radiometric assay (Figure 2 ). Although 10 μM palmitoylcarnitine increased NADPH production by 24 % (P < 0.05), this percentage increased to 61 % with 100 μM palmitoylcarnitine. This stimulation was G6P-dependent, such that 0.1 mM palmitoylcarnitine increased NADPH production 61 % in the presence of 1 mM G6P (Table 1) . Palmitoylcarnitine by itself, without G6P, increased NADPH marginally; evidence that there was little, if any, contamination of the microsomal preparation with mitochondria. The G6P transport inhibitor DIDS (4,4 -di-isothiocyanostilbene-2,2 -disulfonate) inhibited microsomal NADPH accumulation in a dose-dependent manner (Table 1) . Cortisol, as a substrate for the dehydrogenase reaction of 11β-HSD1, amplified microsomal NADPH production 52 % over control (NADP+G6P). This stimulation was additive with that of palmitoylcarnitine (cortisol+palmitoylcarnitine increased NADPH production by 90 % relative to control; Table 1 ). Akin to G6P, both isocitrate and malate at 1 mM increased the microsomal NADPH concentration by 9-and 5-fold respectively. For example, isocitrate increased microsomal NADPH from a mean of 0.08 nmol/mg of protein to 0.77 nmol/mg of protein.
Effect of palmitoylcarnitine and related compounds on 11β-HSD1 reductase
11β-HSD1 reductase, using a substrate (11-dehydrocorticosterone) concentration of 1 μM, was measured in the absence and presence of palmitoylcarnitine against a variety of similar compounds to determine the specificity of its inhibitory action (Figure 3) . Although 10-100 μM palmitoylcarnitine (C 16 ) inhibited the reductase 33-84 %, acetylcarnitine (C 2 ), carnitine and palmitate were ineffective, even at 100 μM. However, myristoylcarnitine (C 14 ) was inhibitory, but less so than palmitoylcarnitine.
DIDS distinctly inhibited 11β-HSD1 reductase, attesting to luminal G6P as an H6PDH substrate (Figure 3 ). Of note, the sensitivity of the enzyme to DIDS inhibition exceeded that observed in the NADPH experiments (Table 1) , because in this latter experimental system a much higher G6P concentration (1 mM) was used. Despite the accrual of NADPH following the addition of isocitrate or malate (Table 1) , these metabolites had a trivial effect on 11β-HSD1 reductase (results not shown), even at concentrations of 5 mM. Purified human liver 11β-HSD1, even after removing any traces of detergent (see the Materials and methods section), was unaffected kinetically by palmitoylcarnitine up to 200 μM. Efforts to restore enzyme inhibition to palmitoylcarnitine by reconstituting with microsomal membrane fragments were unsuccessful (results not shown). Also, the 11β-HSD1 reductase activity in sonicated microsomes which was, as expected, unresponsive to G6P and required added NADPH in the assay, was not inhibited by concentrations up to 200 μM palmitoylcarnitine.
The effect of G6P and palmitoylcarnitine on 11 β-HSD1 dehydrogenase 11β-HSD1 dehydrogenase was inhibited by 14-48 % by 1-10 μM G6P (Figure 4 ). This result compliments the well-recognized stimulation of the oxidoreductase direction consequent to the mass action of NADPH generated from the G6P (Table 1 ). In contrast with its inhibitory action on the oxioreductase, palmitoylcarnitine (200 μM) stimulated 11β-HSD1 dehydrogenase by 66 % (P < 0.001).
Effect of palmitoylcarnitine on flux through H6PDH
H6PDH and 11β-HSD1 reductase are spatially co-localized within the ER lumen, possibly to enhance kinetic efficiency of sequential enzymatic steps and more than likely share the same pyridine nucleotide reservoir [9, 25, 26] . The effect of palmitoylcarnitine on flux through H6PDH was therefore examined. As shown in Figure 5 , 50-200 μM palmitoylcarnitine increased this flux by 10-52 % in intact microsomes (using the radiolabelled CO 2 assay described in the Materials and methods section). In some experiments, H6PDH was measured spectophotometrically with 1 mM G6P and 1 mM NADP and excess 6PGDH such that H6PDH was ratelimiting. Microsomes were pre-incubated with 0-200 μM palmitoylcarnitine for 15 min prior to membrane disruption with 
% CHAPSO {3-[(3-cholamidopropyl)dimethylammonio]-2-
hydroxy-1-propanesulfonic acid}. Using this alternative method, nearly identical findings were apparent as with the CO 2 method (results not shown).
Hence a stimulation of the dehydrogenase activities, H6PDH and 11β-HSD1, by palmitoylcarnitine will collectively amplify the NADPH/NADP nucleotide ratio in the ER lumen.
Microsomal intactness
Liver microsomes remained intact despite incubation for 60 min with increasing concentrations of palmitoylcarnitine at 0.01, 0.05 and 0.150 mM. On the other hand, 0.4-1.0 mM palmitoylcarnitine minimally disrupted the membrane, compared with the detergent CHAPSO, which readily exposed latent glucose dehydrogenase, these higher concentrations reduced latency to 65-75 %. 
DISCUSSION
Within the ER lumen, the equilibrium between inactive (11-oxo) and the active (11β-hydroxy) glucocorticoids is facilitated by 11β-HSD1. By mass action, and given the low free enthalpy change, the balance is dictated more so by the molar ratio of the nicotinamide co-substrates NADPH/NADP + inasmuch as these pyridine compounds exist at logarithmic higher concentrations than the corresponding steroid substrates [17, 27] . This distinct ER pyridine pool co-ordinates the flux through at least two contiguous luminal enzymes, 11β-HSD1 and H6PDH, which share this nucleotide reservoir. The enzymes are apparently spatially colocalized with direct protein-protein engagement, conceivably to promote metabolic channelling [25, 26, 28] .
Reducing equivalents for this pyridine pool are furnished chiefly from the aldehyde oxidation of G6P by H6PDH. Although this enzyme can also utilize fructose 6-phosphate and glucose, their entry with the ER lumen is, in all probability, limited [11] . This is not the case with the predominant intracellular hexose phosphoester G6P, which is actively transported [29] . Also, given that mammalian H6PDH is a bifunctional enzyme with both G6PDH and 6-phoshogluconolactonase activities, stoichiometrically two moles of NADPH are formed per mole of CO 2 released [30] . Although the downstream fate of the product of H6PDH is unknown, the ER of most tissues contains the enzymes which constitute the non-oxidative portion of the pentose pathway, a necessity to avert accumulation of metabolites, thereby allowing unhampered flux [17] .
In the present study, palmitoylcarnitine was found to augment microsomal NADPH accumulatoin (Figure 2) , an outcome which, deductively, should advance the oxidoreductase direction of 11β-HSD1. On the contrary, the reductase direction in intact hepatic microsomes was strikingly inhibited at physiological micromolar concentrations by the acylcarnitine, well within the in vivo values reported in liver. This inhibition depended on the carbon length of the acylcarnitine because palmitate, acetylcarnitine and carnitine had no kinetic impact (Figure 3) .
In addition to attenuating 11β-HSD1 reductase, palmitoylcarnitine stimulated the dehydrogenase direction. For instance, 200 μM palmitoylcarnitine enhanced the dehydrogenase activity by 66 %. Accordingly, the consequence of the acylcarnitine on 11β-HSD1 activity is a restraint on reductase and an increase in dehydrogenase, with the net outcome concurrently tipping the equilibrium balance towards inactive cortisone or, in the rat, 11-dehydrocorticosterone.
The precise concentrations of intracellular long-chain acylcarnitine are, of course, open to question but, in both serum and tissue, the levels depend on the fed or fasted status. On the basis of reported tissue values, liver concentrations of these acyl compounds are in the micromolar range. For instance, in healthy rats, and depending on the fed or fasted state, the longchain acylcarnitine was found to be 6.8 or 41 ng/g of wet weight liver respectively [31, 32] . Assuming that total tissue water in rat liver is 73 % by weight [33, 34] , then these compounds exist in concentrations from 10 to nearly 60 μM. Levels are much higher under pathological conditions such as mutational disorders of fatty acid oxidation. In other rat tissues, such as skeletal muscle and ischaemic heart, acylcarnitine concentrations from 86 to 1950 μM have been reported [35] . In humans, long-chain acylcarnitine in skeletal muscle under normoxic conditions is 0.14 mmol/kg of wet weight (∼180 μM) [36] . Arguably, the kinetic modification of 11β-HSD1, both reductase and dehydrogenase, by palmitoylcarnitine observed in our present study is physiologically meaningful.
As anticipated, the addition of G6P to microsomes caused a 10-fold increase in NADPH ( Table 1 ). Corroborating that the G6P was acting in the ER lumen, this effect of G6P was attenuated in a concentration-dependent manner by DIDS, an anion transport inhibitor which reduces G6P transport [24, 37, 38] . Insofar as G6P provides the substrate for NADPH production, DIDS, as anticipated, also markedly inhibited 11β-HSD1 reductase (Figure 3 ). This inhibitor was selected because other specific, and more commonly tested, G6P transport inhibitors, such as chlorogenic acid or its derivatives, may introduce an experimental artifact, namely a potent antioxidant capacity [39, 40] . Furthermore, on the basis of mass action from the cumulated NADPH, the presumptive kinetic effect of G6P on the dehydrogenase 11β-HSD1 reaction should be inhibitory. Indeed, at 10 μM G6P, the 11β-HSD1 dehydrogenase activity was reduced almost 50 % (Figure 4) .
The combination of G6P and palmitoylcarnitine resulted in a further increment in microsomal NADPH. At 100 μM palmitoylcarnitine, the NADPH accumulation was 68 % over that seen with G6P alone (Figure 2) . Conceivably, this amassment of NADPH due to the acylcarnitine resulted from its tandem antithetical modification of two enzymes: activation of H6PDH and inhibition of 11β-HSD1 reductase. Moreover, the slight activation 11β-HSD1 in the dehydrogenase direction could contribute to the doubling of microsomal NADPH. Which of the two, allegedly coupled, enzymes altered by palmitoylcarnitine played the major role in augmenting microsomal NADPH is uncertain at this time.
The fact that palmitoylcarnitine alone (without G6P) produced only a marginal increase in total reduced pyridine nucleotides (insofar as our reduced pyridine nucleotide microassay detects both NADPH and NADH) is evidence against significant contamination of the microsome preparation with mitochondria. Likewise, if the latter organelles were co-isolated with the microsomes, pyruvate should have altered the total reduced pyridine, yet no effect was observed with up to 1 mM pyruvate (Table 1 ). This increase in NADPH (or NADH) was doubtful due to contamination by non-luminal cytosolic enzymes, such as G6PDH, which conceivably binds loosely to the vesicle's outer membrane throughout the preparation. To confirm this, the NADPH results were identical even after washing the microsomes with 7 % (w/v) poly(ethylene glycol), a procedure which sheds adhered proteins [18] .
As in the mitochondria and cytosol, the ER contains IDH (isocitrate dehydrogenase) and malic enzyme, which could likewise increase luminal NADPH akin to that by H6PDH [18] . Interestingly, in that report, after poly(ethylene glycol) washing and permeabilization, the IDH and H6PDH activities were found to be almost equivalent (2.91 compared with 2.65 nmol/mg of protein per min respectively). Accordingly, if this reduced pyridine nucleotide cofactor generated by isocitrate or malate was added to the same pool shared by H6PDH, the expected kinetic response would be stimulation of 11β-HSD1 reductase. Yet, incongruously, isocitrate or malate, even added to 5 mM to the isolated liver microsomes, was unable to modify 11β-HSD1 reductase activity despite increasing the microsomal NADPH up to 10-fold, a response comparable with that observed with an identical concentration of G6P. Taken together, the results suggest that the NADPH pool manipulated by IDH or malic enzyme is uncoupled from that shared by the G6P/H6PDH/11β-HSD1 tripartate arrangement.
Although extremely high concentrations of amphiphilic acylcarnitines have surfactant physio-chemical properties and can disrupt phospholipid membranes, in the present study no decrease in microsomal intactness was evident at concentrations of less than 0.4 mM (results not shown). Even at this latter concentration, the surrogate ER marker enzyme glucose dehydrogenase was still 60 % latent. Of note, in unilamellar liposomes, impairment of the permeability barrier was not detected until palmitoylcarnitine concentrations approached 0.5 mM [41] . Furthermore, in a comprehensive study of acylcarnitine interactions with model phospholipid bilayers, high levels did not result in gross disruption of the membrane [42] , and it was concluded that the effects of these amphipathic compounds on membrane function are subsequent to their intercalating within phospholipid acyl groups. Because the length of the acyl-carbon chain determines the partition coefficient of the membrane/aqueous phases, we did not perceive any effects on the microsomal enzymes under study, or NADPH, with C 2 -or C 8 -carnitines. Conversely, the longer carbon chained palmitoylcarnitine (C 16 ) and myristoylcarnitine (C 14 ) both inhibited 11β-HSD1 reductase.
The physio-chemical properties and function of membranes are to a large extent governed by their lipid composition, especially the chain length and number of cis-double bonds of the constituent fatty acids. In the present study, only saturated acylcarnitines were tested and, because phospholipids enriched with unsaturated aliphatic chains can increase membrane fluidity, acylcarnitines containing double bond may have disparate effects on 11β-HSD1 than the acyl compound studied here.
As to the possible physiological significance of these findings, it is not altogether implausible that the ER response to acylcarnitines, namely an escalation in NADPH concentration, may be a defensive biochemical adaptation to cellular redox disturbances, glucose deprivation, or several of the manifold reactive oxygen species or nutrient stressors. These are well-known causes of the co-ordinated unfolded protein response following ER detection of metabolic stress. For example, consequent to glucose deprivation and its attendant hypoinsulinaemia, hepatic acylcarnitine increases following the influx of released non-esterified 'free' fatty acids. Although it remains unproven that luminal NADPH defends against ER stress, this appears to hold true at least in human neutrophils. If the ER is deprived of G6P, such as occurs in glycogen storage disease type 1b or if the specific transporter is pharmacologically inhibited, these cells are prone to ER stress [43, 44] . Further validation of the role of luminal NADPH can be appreciated in H6PDH-null mice that develop a skeletal myopathy [45] . Devoid of H6PDH, luminal NADPH production is impaired and ER stress is manifested by overexpression of the unfolded protein response in muscle. Hence, as mentioned above, the microsomal amplification of NADPH in response to palmitoylcarnitine may protect against oxidative or other ER stressors.
In conclusion, in rat liver microsomes, physiological concentrations of palmitoylcarnitine impede 11β-HSD1 reductase and, antithetically, stimulate the dehydrogenase direction of 11β-HSD1, which together bring about a large increase in NADPH levels in microsomes. Additionally, palmitoylcarnitine increases flux through the first two enzymes of the pentose pathway, probably contributing to the accrual of microsomal NADPH. Insofar as the reductase activity of purified 11β-HSD1 and the unpurified enzyme obtained by microsomal rupture were both insensitive to palmitoylcarnitine, plus the fact that H6PDH activity was enhanced, suggest that long-chain acylcarnitines may undo the physical and kinetic H6PDH/11β-HSD1 relationship, thereby impeding the channeling of NADPH between the two. A fracture in this tandem enzyme relationship would explain the attenuation of G6P activation of 11β-HSD1 reductase by H6PDH and perhaps the concurrent stimulation of the unbound H6PDH. Finally, the microsomal luminal NADPH pool shared by the interactive colocalized H6PDH and 11β-HSD1 grouping is disjoined from that supplied by IDH or malic enzyme. 
